No Data
On November 29, livzon pharma (01513) spent HKD 14.6548 million to buy back 0.5483 million shares.
Livzon Pharma (01513) announced that on November 29, 2024, the company invested 14.6548 million...
HK stocks fluctuate | livzon pharma (01513) is now up by more than 4%, planning to repurchase up to 1 billion yuan of A shares. Institutions say Alipza microspheres are expected to be approved.
Livzon Pharma (01513) is currently up over 4%, as of the time of writing, it is up 3.68%, priced at 26.75 HKD, with a transaction volume of 37.1567 million HKD.
格隆汇公告精选︱beijing teamsun technology: AI application related products mainly include "asia vets customer service", "asia vets data assistant", etc.; jizhong energy resources: Controlling shareholders plan to increase shareholding by 0.2 billion yuan to -0.4
【Hotspot Tracking】Beijing Teamsun Technology (600410.SH): The main AI application products are "Asia Vets Customer Service" and "Asia Vets Data Assistant". Guangbo Group Stock (002103.SZ): The proportion of second-dimensional derivative product business to the company's overall revenue is relatively small. GHT Co.,Ltd (300711.SZ): There are no quantum communication related products and solutions launched.【Project Investment】Sirio Pharma (300791.SZ): Plans to invest in building a production base in Thailand for no more than 40 million US dollars. Skyworth Group A (000016.SZ): Plans to invest 1.5 billion yuan to build the Skyworth Asia Vets Smart Drum Washing Machine project.【Contract Awarded】
Express News | Livzon Pharmaceutical Says It Plans to Buy Back and Cancel 600-1000 Mln Yuan Worth of Company Shares Within 12 Months
livzon pharmaceutical group inc. (000513.SZ): proposes to repurchase shares for cancellation in the amount of 0.6 billion yuan to 1 billion yuan
Livzon Pharmaceutical Group Inc. (000513.SZ) announced on November 28 that the company plans to repurchase some of its Renminbi ordinary shares (A shares) through centralized competitive trading. The total amount of the repurchase funds will not be less than 600 million yuan (including) and not more than 1000 million yuan (including). The repurchase price per share will not exceed 45.00 yuan/share (including), and the specific repurchase quantity will be based on the actual number of shares repurchased at the end of the repurchase period. The source of the repurchase funds will be from internal funds or self-raised funds. The implementation period of the share repurchase is from the date when the shareholders' meeting approves the share repurchase plan.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings YetNo Data
No Data
